Novel macrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifungal agents against wild-type and fluconazole resistant Candida species. Macrocyclic compounds 11 and 18 were synthesized through a convergent approach using as a key step a ring-closing metathesis macrocyclization reaction, whereas compounds 25 were obtained by our previously reported synthetic pathway. All the macrocyclic amidinoureas showed antifungal activity toward different Candida species higher or comparable to fluconazole and resulted highly active against fluconazole resistant Candida strains showing in many cases minimum inhibitory concentration values lower than voriconazole
Background: Candida species are one of the most common causes of nosocomial bloodstream infections a...
The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of prepar...
The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of prepar...
Novel macrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifunga...
Novel macrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifunga...
Novel macrocyclic amidinourea derivatives <b>11</b>, <b>18</b>, and <b>25</b> were synthesized and e...
New linear and cyclic guanidines were synthesized and tested in vitro for their antifungal activity ...
New linear and cyclic guanidines were synthesized and tested in vitro for their antifungal activity ...
New linear and cyclic guanidines were synthesized and tested in vitro for their antifungal activity ...
The rise of antimicrobial-resistant phenotypes and the spread of the global pandemic of COVID-19 are...
Systemic fungal infections represent a threat to public health, and annually more than 150 million p...
In the last ten years, we identified and developed a new therapeutic class of antifungal agents, the...
We recently identified a novel family of macrocyclic amidinoureas showing potent antifungal activity...
We recently identified a novel family of macrocyclic amidinoureas showing potent antifungal activity...
Background: Candida species are one of the most common causes of nosocomial bloodstream infections a...
The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of prepar...
The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of prepar...
Novel macrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifunga...
Novel macrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifunga...
Novel macrocyclic amidinourea derivatives <b>11</b>, <b>18</b>, and <b>25</b> were synthesized and e...
New linear and cyclic guanidines were synthesized and tested in vitro for their antifungal activity ...
New linear and cyclic guanidines were synthesized and tested in vitro for their antifungal activity ...
New linear and cyclic guanidines were synthesized and tested in vitro for their antifungal activity ...
The rise of antimicrobial-resistant phenotypes and the spread of the global pandemic of COVID-19 are...
Systemic fungal infections represent a threat to public health, and annually more than 150 million p...
In the last ten years, we identified and developed a new therapeutic class of antifungal agents, the...
We recently identified a novel family of macrocyclic amidinoureas showing potent antifungal activity...
We recently identified a novel family of macrocyclic amidinoureas showing potent antifungal activity...
Background: Candida species are one of the most common causes of nosocomial bloodstream infections a...
The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of prepar...
The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of prepar...